Print this page
-
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-Based Chemotherapy.
Protocol: 082306Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Prostate -
A Phase 3, Randomized, Open-Label Study of MK-5684 (004) Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA).
Protocol: 082307Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Prostate -
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer.
Protocol: 082401Principal Investigator:
-
Biren Saraiya
Applicable Disease Sites: Urinary Bladder -
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT).
Protocol: 082402Principal Investigator:
-
Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment.
Protocol: 082403Principal Investigator:
-
Vignesh Packiam
Applicable Disease Sites: Urinary Bladder -
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations.
Protocol: 082404Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
A Randomized Trial of High-Risk Metachronous OligometastatIc Prostate Cancer with High-Risk Mutations Treated with Metastasis Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS).
Protocol: 082405Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Prostate -
Translational Research on Integrated Predictive Liquid and Excretory biomarkers in Urothelial Carcinoma (TRIPLE-UC)
Protocol: 082412Principal Investigator:
-
Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
The Phase III 'High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer.
Protocol: 082413Principal Investigator:
-
Lara Hathout
Applicable Disease Sites: Prostate -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Any Site
Ovary
Prostate -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
-
Nehal Parikh
Applicable Disease Sites: Other Female Genital
Other Male Genital -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Kidney -
Prostate Cancer Care Communication (PCCC): Impact of Support Person Presence on Communication During Medical Appointments.
Protocol: 132209Principal Investigator:
-
Kathryn Greene
Applicable Disease Sites: Prostate -
Choices About Genetic Testing And Learning Your Risk with Smart Technology (CATALYST).
Protocol: 132307Principal Investigator:
-
Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Other Female Genital
Ovary
Pancreas
Prostate -
Personalized Oncology Promoting Equity for Black Lives (PROPEL).
Protocol: 132309Principal Investigator:
-
Anita Y Kinney
Applicable Disease Sites: Breast
Colon
Corpus Uteri
Ovary
Pancreas
Prostate -
Understanding the Role of p53 in the Development and Progression of Oligometastatic Castration-Sensitive Prostate Cancer.
Protocol: 152102Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Prostate